"We did not miss the sales forecast; Merrill Lynch is the one that missed," said Dan Suesskind, CFO of generic drug giant
, after the company's third-quarter sales of $450 million came in $30 million below Merrill's prediction.
"Teva would have no problem posting sales of another $30 million, even if it lost a little on them, just to keep Merrill Lynch happy," he said. "But we simply don't work that way. We met our own forecasts, which is the main thing -- Why aren't we being asked why, although we missed Merrill Lynch's revenue forecast, we met their earnings forecast?"
The company hit other analysts' sales targets, however.
In response to a question about a possible acquisition of
, the generic division of
, he replied, "We definitely are considering acquisitions of that kind of magnitude."
But, Suesskind continued, "If Mylan contacts us, we'll look into it. They haven't done so yet and at this stage we have no intention of contacting them."
TheMarker is a leading source for technology and business news information in Israel. The site is a venture backed by the Israeli daily Ha'aretz and TheStreet.com. For more stories, go to